Debbie Rigby rounds up the latest in research news

Stability of repackaged dabigatran etexilate capsules in dose administration aids

Removal of dabigatran (Pradaxa) capsules from their original packaging is not recommended by the manufacturer due to sensitivity to moisture. However, this study has clearly demonstrated that if repackaging of Pradaxa capsules is required, storage under refrigerated conditions ensures quality for 28 days.

European Journal of Hospital Pharmacy 2017.

 

Risk of pneumonia associated with incident benzodiazepine use

Analysis of Finnish national registry data suggests that benzodiazepines are associated with an increased risk of pneumonia among patients with Alzheimer disease. Similarly acting non-benzodiazepines (Z-drugs) were not associated with an increased risk of pneumonia. The risk of pneumonia was greatest within the first 30 days of benzodiazepine use (HR 2.09). Sedation associated with benzodiazepine use could increase aspiration risk, which could then lead to pneumonia.

CMAJ April 10, 2017 vol. 189 no. 14

 

Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease

In a randomized clinical trial that included 5108 participants from the community, the cumulative incidence of cardiovascular disease for a median follow-up period of 3.3 years was 11.8% among participants given 100 000 IU of vitamin D3 monthly and 11.5% among those given placebo. The authors concluded that monthly high-dose vitamin D supplementation does not prevent cardiovascular disease and should not be used for this purpose.

JAMA Cardiol. Published online April 5, 2017.

 

Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest

In this Danish nationwide case–time control study, use of nonselective NSAIDs was associated with an increased risk of out-of-hospital cardiac arrest. The result was primarily driven by an increased risk of cardiac arrest in ibuprofen (OR 1.31) and diclofenac (OR 1.50) users.There was no significant association between cardiac arrest and use of the COX-2 selective inhibitors, rofecoxib and celecoxib, nor with the unselective NSAID naproxen.

European Heart Journal – Cardiovascular Pharmacotherapy 2017;3:100-107.